TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06868628: A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)

Sponsor: Tiziana Life Sciences LTD · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$2,988,000

Rescue Site Savings

+$1,958,800

Unlock Full NCT06868628 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06868628 Rescue Dossier →